In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

As a result of the decision, Shilpa will not be eligible to receive FDA approval for its lenvatinib mesylate generic until February 2036.

MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

MoonLake’s stock rocketed 20% after reports claimed Merck made a $3 billion acquisition offer to boost its drug pipeline.

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Population model successfully developed to characterize BI-1910 pharmacokinetics and pharmacodynamics across a broad range of dosesModel will support dose selection for upcoming studies; Phase 2a as ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

German-based BioNTech , best known for its collaboration with Pfizer during the COVID-19 pandemic for developing vaccines, ...

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...